- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Hugel
Market Cap: ₩2.6t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩244,500.00
7D
-0.6%
1Y
-31.3%
Dong-A Socio Holdings
Market Cap: ₩544.2b
Engages in the pharmaceutical business in South Korea.
A000640
₩82,100.00
7D
-3.8%
1Y
-29.3%
Dong-A ST
Market Cap: ₩355.2b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩36,950.00
7D
-3.7%
1Y
-17.5%
Daewoong Pharmaceutical
Market Cap: ₩1.4t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩120,100.00
7D
-0.8%
1Y
-24.1%
PharmaResearch
Market Cap: ₩3.0t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩289,000.00
7D
0.9%
1Y
-33.3%
ST PharmLtd
Market Cap: ₩2.5t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩122,000.00
7D
2.1%
1Y
50.2%